Qyuns Therapeutics Co., Ltd. Announces Significant On-Market Share Repurchase
Key Highlights and Strategic Insights for Investors
Qyuns Therapeutics Co., Ltd. (Stock Code: 2509), a leading biopharmaceutical company listed on the Hong Kong Stock Exchange, has voluntarily announced a substantial on-market share repurchase under its previously granted repurchase mandate. This development, communicated by the Board of Directors, reflects their strong confidence in the company’s intrinsic value and future growth prospects.
Key Points from the Announcement
- Share Repurchase Details: The company has repurchased a total of 3,429,200 ordinary shares on the Hong Kong Stock Exchange, accumulating between November 6, 2025 and the date of this announcement (June 9, 2026).
- Percentage of Total Shares: The repurchased shares represent approximately 1.51% of the existing total number of issued shares as of the announcement date.
- Aggregate Repurchase Amount: The total amount involved in the repurchases is approximately HK\$65.66 million (exclusive of commission and other expenses).
- Repurchase Mandate: The share repurchase was conducted under mandates approved by shareholders at annual general meetings held on June 20, 2025 and May 29, 2026.
- Company’s Position: The Board views the current share price as significantly undervaluing the company, and the repurchase aims to reinforce market confidence and enhance the investment value of the company.
Implications for Shareholders and Investors
- Potential Price Sensitivity: Share repurchases can signal to the market that the company believes its shares are undervalued, often leading to improved investor sentiment and potentially a positive movement in the share price.
- Market Conditions: The Board stressed that the continuation of the share repurchase program remains subject to market conditions and will be at the absolute discretion of the Board or its authorized persons. There are no guarantees regarding timing, quantity, or price of future repurchases.
- Risk Warning: Shareholders and potential investors are advised to exercise caution when dealing in the shares of the company, as the repurchase program’s implementation is not assured and subject to change.
Management and Board Composition
The Board is led by Mr. Qiu Jiwan (Chairman and Executive Director), alongside other executive, non-executive, and independent non-executive directors, underscoring robust corporate governance.
Conclusion
This strategic share repurchase initiative reflects Qyuns Therapeutics’ confidence in its own business outlook and intrinsic value. The buyback could serve as a positive catalyst for the company’s share price, especially if investors interpret it as a strong signal of undervaluation and commitment to shareholder value.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.
